G&E Herbal Biotechnology Co., Ltd. (TPEX:4911)

Market Cap	2.38B -27.6%
Revenue (ttm)	309.13M +24.1%
Net Income	139.20M +36.4%
EPS	2.18 +36.3%
Shares Out	63.72M
PE Ratio	17.13
Forward PE	n/a
Dividend	1.17 (3.12%)
Ex-Dividend Date	Jul 29, 2025

Volume	2,000
Average Volume	63,549
Open	37.35
Previous Close	37.35
Day's Range	37.00 - 37.95
52-Week Range	33.00 - 56.60
Beta	-0.72
RSI	50.47
Earnings Date	May 8, 2026

About G&E Herbal Biotechnology

G&E Herbal Biotechnology Co., Ltd. engages in manufacturing and wholesale of western and chinese medicine, cosmetics, intellectual property rights, biotechnology services, medical device, and other unclassified food products in Taiwan. It offers HepaGent capsules, a liver protective agent; botanical food supplements; botanical anti-aging cosmetics, such as facial cleansing essence, botanic extract toner, moisturizing cream and serum, and essential oil; smile cream and topical gel; as well as lubricants. G&E Herbal Biotechnology Co., Ltd. was fo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 39
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4911

Financial Performance

In 2025, G&E Herbal Biotechnology's revenue was 309.13 million, an increase of 24.13% compared to the previous year's 249.03 million. Earnings were 139.20 million, an increase of 36.38%.